Učitavanje...
Correction of the coagulation defect in hemophilia using a factor Xa variant with novel engineered protease function
Effective therapies are needed to control excessive bleeding in a range of clinical conditions. We describe a surprisingly useful approach to improve hemostasis in vivo using a variant of coagulation factor Xa (FXa(I16L)). This conformationally pliant derivative is partially inactive due to a defect...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157830/ https://ncbi.nlm.nih.gov/pubmed/22020385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nbt.1995 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|